February 12th 2025
Leveraging the DIKW pyramid, SOAP notes, and teamwork for practice efficiency and performance improvement.
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment
View More
Epilepsy and pregnancy: minimizing the risks
January 1st 2004Does maternal epilepsy increase the risk of congenital malformations, or are the antiepileptic drugs to blame? Either way, the primary goal of therapy during pregnancy is to control a woman's seizures while minimizing fetal exposure to anticonvulsive drugs.
Read More
March of Dimes Updates: Integrating genetics into your practice
November 1st 2003Ob/gyns are having to devote significantly more time to medical genetics because of the field's increasing impact on clinical practice. The March of Dimes's new online genetics resource and continuing education program can help you respond to patients'needs with the most up-to-date, customized, and practical information
Read More
Offering high-quality ob/gyn care for lesbian patients
September 1st 2003Most lesbian patients hesitate to reveal their sexual orientation, even though you need that information to deliver targeted health care. Creating a nonjudgmental office environment can encourage trust and disclosure, helping you to better address their unique health needs.
Read More
How do you code for well-woman exams?
April 1st 2002Coding and reimbursement for Medicare well-woman screening exams is one of the biggest challenges in ob/gyn coding. You must know whether a patient meets Medicare's criteria for "high risk" or "low risk." This risk factor determines the frequency with which Medicare pays for well-woman care.
Read More
Cover Story/CME: Evaluation and treatment of unwanted hair growth
February 1st 2002Whether the etiology is androgen excess or something more benign, excess hair growth negatively impacts quality of life for millions of women. A thorough evaluation is required to uncover underlying causes and provide appropriate treatment.
Read More
BRCA1 and BRCA2: Genetic testing and intervention strategies
July 1st 2001Who should undergo genetic testing? Before ordering it, three conditions should be met: There should be a greater than 10% likelihood of a positive test; the ordering physician should be able to interpret the result; and the information should be used to make management decisions.
Read More
CME: Offering mifepristone as an abortion option
February 1st 2001While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug need to familiarize themselves with the research on its advantages and disadvantages.
Read More